-
Nov 4, 2024 | 
healio.com | Cory Perla |Heather Biele |Kris V. Kowdley
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: A wave of new approvals for PBC is redefining the treatment landscape. Triple combination therapy may be a future consideration.
-
Mar 18, 2024 | 
tandfonline.com | Kris V. Kowdley
References Lindor KD, Kowdley KV, Harrison ME. American College of G. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015 May;110(5):646–659. doi: 10.1038/ajg.2015.112. quiz 660 PubMed Web of Science ®Google Scholar Manganis CD, Chapman RW, Culver EL. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020 Jun 21;26(23):3126–3144.
-
Feb 21, 2024 | 
nejm.org | Christopher L. Bowlus |Andreas Kremer |John M. Vierling |Kris V. Kowdley
February 29, 2024N Engl J Med 2024; 390:783-794 DOI: 10.1056/NEJMoa2312100 AbstractEffective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits.
-
Dec 28, 2023 | 
onlinelibrary.wiley.com | Raj Vuppalanchi |Kris V. Kowdley
Individuals with primary biliary cholangitis (PBC) are at risk of progressive liver disease with extra-hepatic symptoms that can significantly diminish health-related quality of life.1, 2 Ursodeoxycholic acid (UDCA) is the first-line agent for treating PBC.1, 2 Obeticholic acid (OCA) was approved in 2016 as a second-line treatment using improvement in alkaline phosphatase (ALP) and bilirubin as surrogate endpoints for accelerated approval using the ‘sub-part H’ pathway.3 Although reduction in...
-
Nov 13, 2023 | 
nejm.org | Kris V. Kowdley |Christopher L. Bowlus |Cynthia Levy |Mario Alvares-da-Silva
November 13, 2023 DOI: 10.1056/NEJMoa2306185 AbstractPrimary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.
-
Nov 13, 2023 | 
nejm.org | Kris V. Kowdley |Christopher L. Bowlus |Cynthia Levy |Mario Alvares-da-Silva
AbstractPrimary biliary cholangitis is a rare, chronic cholestatic liver disease characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver fibrosis. Whether elafibranor, an oral, dual peroxisome proliferator-activated receptor (PPAR) α and δ agonist, may have benefit as a treatment for primary biliary cholangitis is unknown.
-
Oct 17, 2023 | 00250-9/fulltext?rss=yes&sz=64)
thelancet.com | Kris V. Kowdley |John M. Vierling |Nishit B Modi |Kevork Peltekian
Summary Hereditary haemochromatosis protein (HFE)-related haemochromatosis, an inherited iron overload disorder caused by insufficient hepcidin production, results in excessive iron absorption and tissue and organ injury, and is treated with first-line therapeutic phlebotomy. We aimed to investigate the efficacy and safety of rusfertide, a peptidic mimetic of hepcidin, in patients with HFE-related haemochromatosis.
-
Aug 3, 2023 | 
hcplive.com | Kris V. Kowdley |Steven Flamm |Edward Mena |David Victor III
Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD: We’re comingto the end of this discussion, but I want to talk about unmet needs in PBC [primary biliary cholangitis]. What are some unmet needs? I’m going to have everyone comment, but I’m going to start with you, David. David Victor III, MD: This was a lead-in to say that transplantation for patients with PBC is an unmet need.
-
Aug 3, 2023 | 
hcplive.com | Kris V. Kowdley |Steven Flamm |Edward Mena |David Victor III
Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD: There are a lot of new things, like new medications in development. Seladelpar is in a phase 3 trial that’s close to enrollment. Elafibranor is in a phase 3 trial that’s close to enrollment. These are PPAR-Δ and PPAR-⍺-Δ dual agonists. Saroglitazar, which is an PPAR-⍺-γ dual agonist, is also in clinical trials. There’s a fixed-dose combination study that’s ongoing with obeticholic acid and bezafibrate. Sonal, what’s your impression about these trials?
-
Aug 3, 2023 | 
emjreviews.com | David Jones |Robert Mitchell-Thain |Cynthia Levy |Kris V. Kowdley
These industry-sponsored symposia took place on Friday 23rd June as part of the 2023 European Association for the Study of the Liver (EASL) Congress held in Vienna, AustriaChairperson: David Jones1,2Speakers: Robert Mitchell-Thain,3Cynthia Levy,4Kris Kowdley,5Kathryn Houghton,1Alan Bonder61. Newcastle University, UK2. Newcastle Hospitals NHS Foundation Trust, UK3. The PBC Foundation, Edinburgh, UK4.
